Shilova O N, Souslova E A, Pilunov A M, Deyev S M, Petrov R V
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia.
Nizhny Novgorod State University, Nizhny Novgorod, 603600, Russia.
Dokl Biochem Biophys. 2016 Nov;471(1):450-453. doi: 10.1134/S160767291606020X. Epub 2017 Jan 6.
Development of agents for theranostics implies combining the targeting module, the effector module, and the detection module within the same complex or recombinant protein. We have constructed, isolated, and characterized the 4D5scFv-mCherry-PE(40) protein, which exhibits fluorescent properties and specifically binds to cancer cells expressing the HER2 receptor and reduces their viability. The ability of the obtained targeted antitumor agent 4D5scFv-mCherry-PE(40) to selectively stain the HER2-positive cells and its highly selective cytotoxicity against these cells make the obtained targeted recombinant protein 4D5scFv-mCherry-PE(40) a promising theranostic agent for the diagnostics and therapy of HER2-positive human tumors.
用于治疗诊断的试剂的开发意味着在同一复合物或重组蛋白中结合靶向模块、效应模块和检测模块。我们构建、分离并表征了4D5scFv-mCherry-PE(40)蛋白，该蛋白具有荧光特性，能特异性结合表达HER2受体的癌细胞并降低其活力。所获得的靶向抗肿瘤剂4D5scFv-mCherry-PE(40)对HER2阳性细胞进行选择性染色的能力及其对这些细胞的高度选择性细胞毒性，使得所获得的靶向重组蛋白4D5scFv-mCherry-PE(40)成为用于HER2阳性人类肿瘤诊断和治疗的一种有前景的治疗诊断试剂。
